Back

Anthem Biosciences Ltd.

IPO Details · GMP · Subscription · Financials

✅ Listed NSE & BSE Mainboard Live Chart
Issue Price
₹570
Per Share
GMP
NIL
Grey Market
Est. Listing
₹570
Expected Price
Min. Application
₹29,640
2 lots × 26 shares
IPO Issue Details
Issue Price / Price Band₹570 per share (Fixed Price)
Face Value₹2 Per Share
Lot Size26 Shares per Lot
Total Issue Size5,95,75,319 shares (aggregating up to ₹3,395.00 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryOffer For Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenMon, 14 Jul 2025
Subscription CloseWed, 16 Jul 2025
Anchor AllotmentFri, 11 Jul 2025
Basis of AllotmentThu, 17 Jul 2025
Initiation of RefundsFri, 18 Jul 2025
Credit of Shares to DematFri, 18 Jul 2025
Listing DateMon, 21 Jul 2025
UPI Mandate Deadline2025-07-16
Application & Investment Details
Retail — Min (1 Lots)₹14,820 — 26 shares
Retail — Max (13 Lots)₹192,660 (13 Lots)
HNI — Min (14 Lots)₹2,07,480 — 364 shares
EPS (Pre-IPO)₹8.07
EPS (Post-IPO)₹8.07
P/E Ratio (Pre-IPO)70.62x
P/E Ratio (Post-IPO)70.62x
Pre-IPO Promoter Holding56,16,10,051 shares
Post-IPO Promoter Holding56,16,10,051 shares
About Anthem Biosciences Ltd.

Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.Competitive StrengthOne-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.Long-standing relationships with a large, diversified and loyal customer base.Professional and experienced leadership team supported by a qualified scientific talent pool. 

Objects of the Issue

Anthem Biosciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:

1
1 To achieve the benefits of listing the Equity Shares on the Stock Exchanges
Shareholding & Lock-in
Pre-IPO Promoter Holding 56,16,10,051 shares
Post-IPO Promoter Holding 56,16,10,051 shares
Lock-in Period (30%)August 15, 2025
Lock-in Period (50%)October 14, 2025
Check AllotmentCheck Status →
Anthem Biosciences Ltd. — Live Price LIVE
₹570.00
INR · BSE
Fetching live data…
VS Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading chart…
Chart Not Available
Anthem Biosciences Ltd. is not yet listed on Yahoo Finance or has a different ticker symbol.
Try again after listing stabilises (2-3 trading days).
Issue ₹570.00 Live Price
Quick Facts
GMP Signal ⚪ No GMP
StatusListed
Issue Price₹570
GMPNIL
Est. Listing₹570
Lot Size26 shares
Min Amount₹29,640
Listing Date21 Jul 2025
Disclaimer: GMP is unofficial and unregulated. It does not guarantee actual listing price.
Listing Performance
Issue Price₹570
Listing Date21 Jul 2025
Listing Price
Listing Gain/Loss—%
52-Week High
52-Week Low
Issue Structure & Reservation
Category Shares Offered % Issue Amount (₹ Cr)* Subscription
TOTAL 59,575,319 100.00% ₹3,395.79 Cr
* Based on ₹570.00 (upper price band)
Lot Size & Investment Details
Lot Size
26
Shares
Issue Price
₹570.00
Per Share
Min Investment
₹14,820
1 Lot
Category Lots Shares Amount (₹)
Retail (Min) 1 26 ₹14,820
Retail (Max) 13 338 ₹192,660
sNII (Min) 14 364 ₹207,480
bNII (Min) 68 1,768 ₹1,007,760
Company Financials — Restated Consolidated (Amount in Crore)
Particulars31 Mar 202531 Mar 202431 Mar 2023
Revenue from Operations 1930.29 1483.07 1133.99
EBITDA 683.78 519.96 446.05
Profit After Tax (PAT) 451.26 367.31 385.19
Net Worth 2409.86 1924.66 1740.67
Total Assets 2807.58 2398.11 2014.46
Reserves & Surplus 2298.05 1815.39 1628.88
Total Borrowings 108.95 232.53 125.06
Key Ratios & Valuation
Issue Price ₹570
Face Value ₹2 Per Share
P/BV 13.23
RoE 20.82%
RoCE 26.88%
RoNW 20.82%
PAT Margin (%) 23.38%
EBITDA Margin (%) 36.81%
Debt / Equity 0.05
Company Details
Company
Anthem Biosciences Ltd.
Exchange
NSE & BSE
IPO Type
Mainboard IPO
Issue Type
Bookbuilding IPO
Face Value
₹2 Per Share
Script Code
N/A
Address
No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099
Book Running Lead Managers
JM Financial Ltd.
Book Running Lead Manager (BRLM)
Citigroup Global Markets India Pvt.Ltd.
Book Running Lead Manager (BRLM)
JP Morgan India Pvt.Ltd.
Book Running Lead Manager (BRLM)
Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Book Running Lead Manager (BRLM)